Skip to main content
Mohammad Arfat Ganiyani on Muck Rack

Mohammad Arfat Ganiyani

As seen in: Newswise, UroToday
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mohammad Arfat

Contact Mohammad Arfat, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Carcinoma in the Era of Emerging Systemic Therapy: A Retrospective Cohort Study.

|
By Mohammad Arfat Ganiyani, Hiba Narvel, Mrudula Thiriveedi
| UroToday Verified
Background: Renal cell carcinoma accounts for nearly 15,000 deaths annually in the US, and approximately 30-40% of patients present with metastatic disease (mRCC). The advent of immune checkpoint inhibitors (IO) and tyrosine kinase inhibitors (TKI) has revolutionized the treatment paradigm of patients with mRCC. However, the role of cytoreductive nephrectomy (CN) in the IO-TKI era, particularly for rare and understudied histologies such as non-clear-cell RCC, remains poorly understood.
Open in Who Shared Issue with article?

Survival outcomes of small cell variant bladder ca

|
By Mohammad Arfat Ganiyani
| Newswise
Research Alert Newswise — Background:Small cell carcinoma of bladder (SCB) is a rare and aggressive histological subtype. While the survival impact of various treatment modalities for the classic urothelial bladder cancer has been well-researched, limited studies exists on the survival outcomes of these treatment modalities in patients with SCB, primarily due to the exclusion of these patients from clinical trials.
Open in Who Shared Issue with article?
See all 2 articles